Clinical Trial Search

Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken

Primary: Generalized Anxiety Disorder-7 (Gad-7) — 14.86; 12.88; 8.33; 7.62 units on a scale

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Change From Baseline in the Tablet Routine Questionaire (TRQ) "Past Month" Item at 24 Weeks — 21.5; 28.0 percent of medications not taken

Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: Proportion of Days Covered With Medicine — 0.69 Proportion of days covered with medicine

Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation

Primary: Change in Treatment Non-adherence as Measured by the Tablets Routine Questionnaire (TRQ) (Past Month) — -23.6 percentage of medication not taken — p=<0.001

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001

Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days

Primary: Electronically Measured Mean Medication Adherence During Intervention — 87; 95; 92 Percentage of Timely Med Adherence

Primary: Change in Medication Adherence as Measured by the Adherence to Refills and Medications Scale (ARMS) — -4.0; -1.0 score on a scale

Primary: Medication Adherence at Baseline and 6-month Follow-up Period — 59.4; 55.95 units on a scale

Primary: Adherence — 91.84; 88.61; 72.55 Percentage of medication taken

Primary: Medication Adherence — 93.08; 89.52 percentage of doses recorded as taken — p=0.28

Primary: Electronically Monitored Adherence — 45.5; 50.5 units on a scale — p=0.002

Primary: Percentage of Adherent Participants — 65; 38 percentage of participants — p==0.004

Primary: Mean Adherence Rate at the End of the Study (Visit 3) — 0.37 proportion of days

Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale